Free Trial
→ Here’s How to Claim Your Stake in Elon’s Private Company, xAI (From Brownstone Research) (Ad) Buy ARQT Stock  Free ARQT Stock Alerts

Arcutis Biotherapeutics (ARQT) Financials

Arcutis Biotherapeutics logo
$13.07 +0.13 (+1.00%)
As of 01:52 PM Eastern
Compare
Annual Income Statements for Arcutis Biotherapeutics

Annual Income Statements for Arcutis Biotherapeutics

This table shows Arcutis Biotherapeutics' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2018 2019 2020 2021 2022 2023 2024
Net Income / (Loss) Attributable to Common Shareholders		 -19 -42 -136 -206 -311 -262 -140
Consolidated Net Income / (Loss)		 -19 -42 -136 -206 -311 -262 -140
Net Income / (Loss) Continuing Operations		 -19 -42 -136 -206 -311 -262 -140
Total Pre-Tax Income 		-19 -42 -136 -206 -311 -259 -156
Total Operating Income		 -20 -43 -137 -207 -302 -241 -128
Total Gross Profit		 0.00 0.00 0.00 0.00 2.93 55 177
Total Revenue		 0.00 0.00 0.00 0.00 3.69 60 197
Operating Revenue		 - - 0.00 0.00 3.69 60 197
Total Cost of Revenue		 0.00 0.00 0.00 0.00 0.75 4.99 19
Operating Cost of Revenue		 - - 0.00 0.00 0.75 4.99 19
Total Operating Expenses		 20 43 137 207 305 296 306
Selling, General & Admin Expense		 1.80 6.61 21 61 122 185 229
Research & Development Expense		 18 37 115 146 182 111 76
Total Other Income / (Expense), net		 0.48 1.14 0.97 0.17 -9.83 -18 -27
Interest Expense		 - - 0.00 0.00 16 30 27
Income Tax Expense		 - - - - 0.00 3.11 0.65
Other Gains / (Losses), net		 - - - - - - 16
Basic Earnings per Share		 ($15.53) ($22.78) ($3.80) ($4.18) ($5.66) ($3.78) ($1.16)
Weighted Average Basic Shares Outstanding		 1.24M 1.84M 35.67M 49.41M 55.03M 69.31M 120.96M
Diluted Earnings per Share		 ($15.53) ($22.78) ($3.80) ($4.18) ($5.66) ($3.78) ($1.16)
Weighted Average Diluted Shares Outstanding		 1.24M 1.84M 35.67M 49.41M 55.03M 69.31M 120.96M
Weighted Average Basic & Diluted Shares Outstanding		 1.24M 1.84M 35.67M 50.38M 61.08M - 118.64M

Quarterly Income Statements for Arcutis Biotherapeutics

This table shows Arcutis Biotherapeutics' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q3 2022 Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024
Net Income / (Loss) Attributable to Common Shareholders		 -108 -72 -80 -71 -45 -66 -35 -52 -42 -11
Consolidated Net Income / (Loss)		 -108 -72 -80 -71 -45 -66 -35 -52 -42 -11
Net Income / (Loss) Continuing Operations		 -108 -72 -80 -71 -45 -66 -35 -52 -42 -11
Total Pre-Tax Income 		-108 -72 -80 -71 -42 -66 -35 -52 -42 -27
Total Operating Income		 -105 -68 -76 -67 -37 -61 -32 -50 -39 -7.63
Total Gross Profit		 0.46 2.48 2.00 4.41 37 11 46 27 39 64
Total Revenue		 0.73 2.96 2.78 5.19 38 14 50 31 45 71
Operating Revenue		 0.73 - 2.78 5.19 38 14 50 31 45 71
Total Cost of Revenue		 0.27 0.49 0.78 0.78 1.18 2.25 3.26 3.46 5.50 6.91
Operating Cost of Revenue		 0.27 - 0.78 0.78 1.18 2.25 3.26 3.46 5.50 6.91
Total Operating Expenses		 105 71 78 71 74 72 78 77 78 72
Selling, General & Admin Expense		 35 37 43 46 48 49 55 58 59 58
Research & Development Expense		 70 34 35 25 26 24 23 19 20 14
Total Other Income / (Expense), net		 -2.96 -3.60 -3.84 -4.23 -4.84 -5.03 -3.44 -2.26 -2.47 -19
Interest Expense		 4.90 6.92 7.04 7.35 7.56 7.76 7.48 7.48 6.65 5.55
Income Tax Expense		 0.00 - 0.00 0.00 3.02 0.09 0.32 0.00 0.00 0.32
Basic Earnings per Share		 ($1.89) ($1.19) ($1.31) ($1.16) ($0.73) ($0.58) ($0.32) ($0.42) ($0.33) ($0.09)
Weighted Average Basic Shares Outstanding		 57.09M 55.03M 61.17M 61.43M 61.73M 69.31M 111.05M 123.48M 124.30M 120.96M
Diluted Earnings per Share		 ($1.89) ($1.19) ($1.31) ($1.16) ($0.73) ($0.58) ($0.32) ($0.42) ($0.33) ($0.09)
Weighted Average Diluted Shares Outstanding		 57.09M 55.03M 61.17M 61.43M 61.73M 69.31M 111.05M 123.48M 124.30M 120.96M
Weighted Average Basic & Diluted Shares Outstanding		 60.93M 61.08M 61.42M 61.65M 94.38M 0.00 115.76M 116.89M 117.04M 118.64M

Annual Cash Flow Statements for Arcutis Biotherapeutics

This table details how cash moves in and out of Arcutis Biotherapeutics' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2018 2019 2020 2021 2022 2023 2024
Net Change in Cash & Equivalents		 36 24 3.29 31 -43 34 -17
Net Cash From Operating Activities		 -14 -43 -113 -175 -258 -247 -112
Net Cash From Continuing Operating Activities		 -14 -43 -113 -175 -258 -247 -112
Net Income / (Loss) Continuing Operations		 -19 -42 -136 -206 -311 -262 -140
Consolidated Net Income / (Loss)		 -19 -42 -136 -206 -311 -262 -140
Depreciation Expense		 0.00 0.07 0.12 0.45 0.62 0.77 0.64
Amortization Expense		 -0.01 -0.35 0.07 3.45 -1.94 -6.24 -4.94
Non-Cash Adjustments To Reconcile Net Income		 3.08 0.95 8.32 24 65 44 47
Changes in Operating Assets and Liabilities, net		 2.11 -1.51 14 3.62 -10 -24 -15
Net Cash From Investing Activities		 -12 -26 -182 -76 -87 180 29
Net Cash From Continuing Investing Activities		 -12 -26 -182 -76 -87 180 29
Purchase of Property, Plant & Equipment		 0.00 -0.30 -0.32 -1.00 -0.33 -0.43 -0.14
Acquisitions		 - - 0.00 0.00 -23 0.00 -5.00
Purchase of Investments		 -12 -61 -279 -293 -415 -226 -255
Sale and/or Maturity of Investments		 0.00 35 98 218 351 407 289
Net Cash From Financing Activities		 62 93 298 282 302 101 66
Net Cash From Continuing Financing Activities		 62 93 298 282 302 101 66
Repayment of Debt		 0.00 -1.40 0.00 -1.64 -2.19 0.00 -100
Issuance of Debt		 - 0.00 0.00 74 125 0.00 0.00
Issuance of Common Equity		 0.00 0.00 298 208 178 100 163
Other Financing Activities, net		 0.39 0.27 0.53 1.27 1.02 1.25 2.81
Effect of Exchange Rate Changes		 - - - - 0.00 -0.05 -0.24
Cash Interest Paid		 - 0.00 0.00 0.14 13 25 22

Quarterly Cash Flow Statements for Arcutis Biotherapeutics

This table details how cash moves in and out of Arcutis Biotherapeutics' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q3 2022 Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024
Net Change in Cash & Equivalents		 20 -28 27 24 2.36 -19 101 -106 51 -64
Net Cash From Operating Activities		 -68 -71 -80 -66 -44 -56 -32 -45 -35 -0.75
Net Cash From Continuing Operating Activities		 -68 -71 -80 -66 -44 -56 -32 -44 -35 -0.75
Net Income / (Loss) Continuing Operations		 -108 -72 -80 -71 -45 -66 -35 -52 -42 -11
Consolidated Net Income / (Loss)		 -108 -72 -80 -71 -45 -66 -35 -52 -42 -11
Depreciation Expense		 0.16 0.16 0.18 0.20 0.20 0.20 0.17 0.16 0.16 0.15
Amortization Expense		 -0.68 -2.16 -1.97 -1.64 -1.35 -1.29 -1.54 -2.20 -0.42 -0.78
Non-Cash Adjustments To Reconcile Net Income		 39 10 11 12 11 11 11 14 10 12
Changes in Operating Assets and Liabilities, net		 1.23 -7.41 -9.01 -5.73 -9.18 0.41 -5.44 -4.27 -3.80 -1.57
Net Cash From Investing Activities		 -197 42 108 89 46 -62 -29 -62 85 35
Net Cash From Continuing Investing Activities		 -197 42 108 89 46 -62 -29 -62 85 35
Purchase of Investments		 -242 -38 -40 -46 -22 -118 -106 -126 -5.69 -17
Sale and/or Maturity of Investments		 67 80 148 135 68 56 77 64 91 57
Net Cash From Financing Activities		 285 0.96 0.10 1.07 0.87 99 162 1.46 0.39 -97
Net Cash From Continuing Financing Activities		 285 0.96 0.10 1.07 0.87 99 162 1.46 0.39 -97
Issuance of Common Equity		 162 0.95 0.00 0.99 - 99 162 0.65 - 1.06
Other Financing Activities, net		 0.58 0.02 0.10 0.07 0.87 0.21 0.08 0.81 0.39 1.53
Effect of Exchange Rate Changes		 - - -0.05 0.01 -0.08 0.07 -0.07 -0.03 0.10 -0.23
Cash Interest Paid		 3.93 5.71 6.00 6.31 6.55 6.58 6.51 6.51 6.23 2.96

Annual Balance Sheets for Arcutis Biotherapeutics

This table presents Arcutis Biotherapeutics' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2019 2020 2021 2022 2023 2024
Total Assets		 107 298 408 449 341 349
Total Current Assets		 106 293 403 437 330 336
Cash & Equivalents		 63 65 96 54 88 71
Restricted Cash		 0.00 1.54 1.54 1.23 0.93 0.62
Short-Term Investments		 38 219 291 356 183 157
Accounts Receivable		 - - 0.00 8.46 26 73
Inventories, net		 - - 0.00 7.51 13 15
Prepaid Expenses		 5.21 6.84 14 11 19 20
Plant, Property, & Equipment, net		 0.23 2.02 2.26 1.88 1.54 1.04
Total Noncurrent Assets		 0.31 3.43 3.12 9.99 9.40 12
Intangible Assets		 - - 0.00 7.19 6.44 9.48
Other Noncurrent Operating Assets		 0.31 3.43 3.12 2.80 2.96 2.55
Total Liabilities & Shareholders' Equity		 107 298 408 449 341 349
Total Liabilities		 5.55 28 110 240 253 191
Total Current Liabilities		 5.24 23 33 38 47 81
Accounts Payable		 1.41 7.14 7.35 8.83 12 14
Accrued Expenses		 3.65 15 26 28 34 66
Other Current Liabilities		 0.18 0.00 0.43 0.66 0.74 0.82
Total Noncurrent Liabilities		 0.31 5.05 77 202 206 110
Long-Term Debt		 - - 72 198 202 107
Other Noncurrent Operating Liabilities		 0.31 5.05 4.80 4.12 4.23 3.13
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 -65 271 298 210 89 158
Total Preferred & Common Equity		 -65 271 298 210 89 158
Preferred Stock		 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 -65 271 298 210 89 158
Common Stock		 1.24 473 706 930 1,071 1,279
Retained Earnings		 -66 -202 -408 -720 -982 -1,122
Accumulated Other Comprehensive Income / (Loss)		 -0.00 -0.00 -0.26 -1.09 0.00 -0.01

Quarterly Balance Sheets for Arcutis Biotherapeutics

This table presents Arcutis Biotherapeutics' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q3 2022 Q1 2023 Q2 2023 Q3 2023 Q1 2024 Q2 2024 Q3 2024
Total Assets		 509 379 321 293 479 445 437
Total Current Assets		 497 368 309 282 468 435 424
Cash & Equivalents		 82 81 105 107 190 84 135
Restricted Cash		 1.23 0.93 0.93 0.93 0.62 0.62 0.62
Short-Term Investments		 395 251 164 120 214 278 196
Accounts Receivable		 2.43 13 17 19 37 43 60
Inventories, net		 4.31 8.55 10 14 13 14 14
Prepaid Expenses		 12 13 12 20 13 14 18
Plant, Property, & Equipment, net		 1.94 2.07 1.87 1.74 1.37 1.35 1.19
Total Noncurrent Assets		 10 9.71 9.95 9.68 9.11 8.82 12
Intangible Assets		 7.38 7.00 6.81 6.63 6.25 6.06 9.79
Other Noncurrent Operating Assets		 2.88 2.71 3.14 3.05 2.86 2.76 2.66
Total Liabilities & Shareholders' Equity		 509 379 321 293 479 445 437
Total Liabilities		 238 240 240 246 254 258 281
Total Current Liabilities		 37 37 37 42 47 51 172
Short-Term Debt		 - - - - - - 100
Accounts Payable		 8.67 12 17 13 13 7.94 19
Accrued Expenses		 28 24 19 28 34 43 53
Other Current Liabilities		 0.64 0.68 0.70 0.72 0.76 0.78 0.80
Total Noncurrent Liabilities		 201 203 204 204 206 207 108
Long-Term Debt		 197 199 200 201 203 204 105
Other Noncurrent Operating Liabilities		 4.29 3.94 3.76 3.57 3.49 3.17 3.19
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 271 140 81 47 225 186 157
Total Preferred & Common Equity		 271 140 81 47 225 186 157
Preferred Stock		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 271 140 81 47 225 186 157
Common Stock		 920 940 952 963 1,242 1,256 1,267
Retained Earnings		 -648 -800 -871 -916 -1,017 -1,070 -1,111
Accumulated Other Comprehensive Income / (Loss)		 -1.60 -0.41 -0.29 -0.18 -0.13 -0.29 0.53

Annual Metrics and Ratios for Arcutis Biotherapeutics

This table displays calculated financial ratios and metrics derived from Arcutis Biotherapeutics' official financial filings.

Metric 2018 2019 2020 2021 2022 2023 2024
Growth Metrics		 - - - - - - -
Revenue Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 1,517.09% 229.74%
EBITDA Growth		 0.00% -119.43% -220.43% -49.43% -46.77% 20.98% 43.48%
EBIT Growth		 0.00% -118.10% -223.07% -52.09% -43.35% 22.48% 44.01%
NOPAT Growth		 0.00% -118.56% -216.81% -51.14% -46.05% 20.07% 46.75%
Net Income Growth		 0.00% -118.10% -223.07% -52.09% -50.93% 15.83% 46.58%
EPS Growth		 0.00% -46.68% 83.32% -10.00% -35.41% 33.22% 69.31%
Operating Cash Flow Growth		 0.00% -204.13% -163.87% -54.49% -47.58% 4.14% 54.60%
Free Cash Flow Firm Growth		 0.00% 0.00% -163.55% -76.49% -60.05% 16.05% 42.94%
Invested Capital Growth		 0.00% 0.00% -7,897.97% -20.91% 81.30% 609.07% 104.59%
Revenue Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 408.41% 21.54% 0.00%
EBITDA Q/Q Growth		 0.00% 0.00% -18.44% -22.12% 1.07% 3.13% 0.00%
EBIT Q/Q Growth		 0.00% 0.00% -18.81% -22.05% 2.06% 2.83% 0.00%
NOPAT Q/Q Growth		 0.00% 0.00% -18.23% -21.98% 0.94% 2.92% 0.00%
Net Income Q/Q Growth		 0.00% 0.00% -18.81% -22.05% -0.22% 2.14% 0.00%
EPS Q/Q Growth		 0.00% 0.00% 60.21% -21.51% 4.23% 13.90% 0.00%
Operating Cash Flow Q/Q Growth		 0.00% 0.00% -16.22% -12.31% -8.12% 5.66% 0.00%
Free Cash Flow Firm Q/Q Growth		 0.00% 0.00% 0.00% -9.29% -8.62% 6.89% -921.49%
Invested Capital Q/Q Growth		 0.00% 0.00% 7.69% -219.31% 67.45% -9.16% 20.29%
Profitability Metrics		 - - - - - - -
Gross Margin		 0.00% 0.00% 0.00% 0.00% 79.54% 91.63% 90.27%
EBITDA Margin		 0.00% 0.00% 0.00% 0.00% -8,060.91% -393.89% -67.52%
Operating Margin		 0.00% 0.00% 0.00% 0.00% -8,183.04% -404.49% -65.33%
EBIT Margin		 0.00% 0.00% 0.00% 0.00% -8,025.12% -384.72% -65.33%
Profit (Net Income) Margin		 0.00% 0.00% 0.00% 0.00% -8,449.76% -439.79% -71.25%
Tax Burden Percent		 100.00% 100.00% 100.00% 100.00% 100.00% 101.20% 90.02%
Interest Burden Percent		 100.00% 100.00% 100.00% 100.00% 105.29% 112.96% 121.16%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% -2,375.88% -333.80%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% -2,310.14% -281.64%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 2,200.09% 220.04%
Return on Equity (ROE)		 0.00% -41.39% -72.93% -72.62% -122.80% -175.79% -113.76%
Cash Return on Invested Capital (CROIC)		 0.00% -30,852.18% 0.00% 0.00% 0.00% -1,074.23% -402.47%
Operating Return on Assets (OROA)		 0.00% 0.00% 0.00% 0.00% -69.00% -58.01% -37.20%
Return on Assets (ROA)		 0.00% 0.00% 0.00% 0.00% -72.65% -66.31% -40.58%
Return on Common Equity (ROCE)		 0.00% 26.53% -40.30% -72.62% -122.80% -175.79% -113.76%
Return on Equity Simple (ROE_SIMPLE)		 0.00% 64.58% -50.14% -69.32% -148.61% -295.65% -88.89%
Net Operating Profit after Tax (NOPAT)		 -14 -30 -96 -145 -211 -169 -90
NOPAT Margin		 0.00% 0.00% 0.00% 0.00% -5,728.13% -283.14% -45.73%
Net Nonoperating Expense Percent (NNEP)		 0.00% -23.31% -20.67% -20.52% -37.91% -65.74% -52.15%
Return On Investment Capital (ROIC_SIMPLE)		 - - - - -51.83% -58.10% -33.95%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 20.46% 8.37% 9.73%
SG&A Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 3,313.19% 310.61% 116.71%
R&D to Revenue		 0.00% 0.00% 0.00% 0.00% 4,949.40% 185.51% 38.88%
Operating Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 8,262.59% 496.12% 155.60%
Earnings before Interest and Taxes (EBIT)		 -19 -42 -136 -206 -296 -229 -128
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -19 -42 -135 -202 -297 -235 -133
Valuation Ratios		 - - - - - - -
Price to Book Value (P/BV)		 0.00 0.00 4.54 3.50 4.30 3.44 10.35
Price to Tangible Book Value (P/TBV)		 0.00 0.00 4.54 3.50 4.46 3.71 11.01
Price to Revenue (P/Rev)		 0.00 0.00 0.00 0.00 244.64 5.11 8.30
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 1,140.11 0.00 0.00 0.00 13.23 41.72
Enterprise Value to Revenue (EV/Rev)		 0.00 0.00 0.00 0.00 186.84 3.92 7.68
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - -
Debt to Equity		 0.00 0.00 0.00 0.24 0.94 2.28 0.68
Long-Term Debt to Equity		 0.00 0.00 0.00 0.24 0.94 2.28 0.68
Financial Leverage		 0.00 -1.00 -1.04 -1.06 -1.04 -0.95 -0.78
Leverage Ratio		 0.00 1.05 1.09 1.24 1.69 2.65 2.80
Compound Leverage Factor		 0.00 1.05 1.09 1.24 1.78 2.99 3.40
Debt to Total Capital		 0.00% 0.00% 0.00% 19.55% 48.55% 69.47% 40.49%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 19.55% 48.55% 69.47% 40.49%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 164.09% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 0.00% -64.09% 100.00% 80.45% 51.45% 30.53% 59.51%
Debt to EBITDA		 0.00 0.00 0.00 -0.36 -0.67 -0.86 -0.81
Net Debt to EBITDA		 0.00 0.00 0.00 1.56 0.72 0.30 0.91
Long-Term Debt to EBITDA		 0.00 0.00 0.00 -0.36 -0.67 -0.86 -0.81
Debt to NOPAT		 0.00 0.00 0.00 -0.50 -0.94 -1.20 -1.19
Net Debt to NOPAT		 0.00 0.00 0.00 2.19 1.01 0.42 1.35
Long-Term Debt to NOPAT		 0.00 0.00 0.00 -0.50 -0.94 -1.20 -1.19
Altman Z-Score		 0.00 16.20 25.28 3.68 -1.08 -4.35 0.84
Noncontrolling Interest Sharing Ratio		 0.00% 164.09% 44.75% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - -
Current Ratio		 0.00 20.33 12.96 12.09 11.57 7.08 4.15
Quick Ratio		 0.00 19.34 12.58 11.61 11.06 6.38 3.72
Cash Flow Metrics		 - - - - - - -
Free Cash Flow to Firm (FCFF)		 0.00 -30 -80 -141 -226 -190 -108
Operating Cash Flow to CapEx		 0.00% -14,520.68% -35,212.77% -17,550.45% -77,391.89% -57,723.60% -78,432.17%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 -14.45 -6.39 -3.99
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 0.00 -16.47 -8.32 -4.13
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 -16.49 -8.33 -4.13
Efficiency Ratios		 - - - - - - -
Asset Turnover		 0.00 0.00 0.00 0.00 0.01 0.15 0.57
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00 3.48 3.98
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.48 1.38
Fixed Asset Turnover		 0.00 0.00 0.00 0.00 1.78 34.86 152.36
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.09 0.48 1.46
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 0.00 104.91 91.81
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 755.62 263.90
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 3,916.25 761.87 250.09
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 0.00 -3,916.25 98.65 105.62
Capital & Investment Metrics		 - - - - - - -
Invested Capital		 0.00 0.20 -15 -19 -3.47 18 36
Invested Capital Turnover		 0.00 0.00 0.00 0.00 -0.33 8.39 7.30
Increase / (Decrease) in Invested Capital		 0.00 0.20 -16 -3.21 15 21 18
Enterprise Value (EV)		 0.00 225 941 727 689 234 1,509
Market Capitalization		 159 159 1,227 1,043 902 305 1,630
Book Value per Share		 $0.00 ($35.28) $6.20 $5.92 $3.44 $0.94 $1.35
Tangible Book Value per Share		 $0.00 ($35.28) $6.20 $5.92 $3.32 $0.87 $1.27
Total Capital		 0.00 101 271 370 407 290 265
Total Debt		 0.00 0.00 0.00 72 198 202 107
Total Long-Term Debt		 0.00 0.00 0.00 72 198 202 107
Net Debt		 0.00 -101 -286 -316 -213 -71 -121
Capital Expenditures (CapEx)		 0.00 0.30 0.32 1.00 0.33 0.43 0.14
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 0.00 -0.03 -16 -19 -11 11 26
Debt-free Net Working Capital (DFNWC)		 0.00 101 270 369 400 284 255
Net Working Capital (NWC)		 0.00 101 270 369 400 284 255
Net Nonoperating Expense (NNE)		 5.44 12 40 62 100 93 50
Net Nonoperating Obligations (NNO)		 0.00 -101 -286 -316 -213 -71 -121
Total Depreciation and Amortization (D&A)		 -0.01 -0.29 0.19 3.91 -1.32 -5.47 -4.30
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% -304.50% 18.42% 13.35%
Debt-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 10,840.99% 476.06% 129.65%
Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 10,840.99% 476.06% 129.65%
Earnings Adjustments		 - - - - - - -
Adjusted Basic Earnings per Share		 $0.00 $0.00 ($3.80) ($4.18) ($5.66) $0.00 ($1.16)
Adjusted Weighted Average Basic Shares Outstanding		 0.00 0.00 50.08M 49.41M 55.03M 0.00 120.96M
Adjusted Diluted Earnings per Share		 $0.00 $0.00 ($3.80) ($4.18) ($5.66) $0.00 ($1.16)
Adjusted Weighted Average Diluted Shares Outstanding		 0.00 0.00 50.08M 49.41M 55.03M 0.00 120.96M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 ($3.80) $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 0.00 0.00 35.67M 50.38M 61.08M 0.00 118.64M
Normalized Net Operating Profit after Tax (NOPAT)		 -14 -30 -96 -145 -211 -169 -90
Normalized NOPAT Margin		 0.00% 0.00% 0.00% 0.00% -5,728.13% -283.14% -45.73%
Pre Tax Income Margin		 0.00% 0.00% 0.00% 0.00% -8,449.76% -434.57% -79.15%
Debt Service Ratios		 - - - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 0.00 -18.90 -7.72 -4.73
NOPAT to Interest Expense		 0.00 0.00 0.00 0.00 -13.49 -5.68 -3.31
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 -18.92 -7.73 -4.73
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 -13.51 -5.69 -3.31
Payout Ratios		 - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Quarterly Metrics and Ratios for Arcutis Biotherapeutics

This table displays calculated financial ratios and metrics derived from Arcutis Biotherapeutics' official financial filings.

Metric Q3 2022 Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024
Growth Metrics		 - - - - - - - - - -
Revenue Growth		 0.00% 0.00% 0.00% 0.00% 5,156.41% 356.81% 1,682.42% 494.57% 17.44% 427.58%
EBITDA Growth		 -85.48% 4.56% -21.29% -0.16% 65.81% 11.30% 61.33% 27.96% 0.52% 86.11%
EBIT Growth		 -80.43% 8.72% -16.92% 2.70% 66.75% 10.25% 62.25% 29.53% -2.05% 86.94%
NOPAT Growth		 -83.52% 4.01% -21.77% -1.42% 64.77% 10.60% 58.54% 24.99% -5.86% 87.52%
Net Income Growth		 -89.03% -0.97% -24.53% -5.32% 58.44% 7.96% 55.83% 26.28% 7.21% 83.72%
EPS Growth		 -65.79% 17.36% -3.15% 11.45% 61.38% 51.26% 75.57% 63.79% 54.79% 84.48%
Operating Cash Flow Growth		 -65.58% -37.43% -41.02% -7.27% 35.03% 20.86% 60.67% 32.14% 21.14% 98.67%
Free Cash Flow Firm Growth		 -34.84% -34.93% -266.17% -161.80% 18.26% -1.55% 47.66% 28.69% 32.18% 62.74%
Invested Capital Growth		 -83.43% 81.30% 128.19% 171.76% 282.40% 609.07% 350.38% 154.53% 54.51% 104.59%
Revenue Q/Q Growth		 0.00% 308.41% -6.08% 86.62% 634.28% -64.51% 0.00% -37.75% 45.04% 59.45%
EBITDA Q/Q Growth		 -59.02% 35.06% -11.56% 13.06% 45.72% -68.48% 0.00% -61.98% 25.04% 76.47%
EBIT Q/Q Growth		 -57.19% 36.68% -12.22% 12.89% 46.29% -70.94% 0.00% -62.62% 22.22% 78.12%
NOPAT Q/Q Growth		 -59.13% 34.68% -11.46% 12.46% 44.72% -65.75% 0.00% -58.36% 21.99% 80.46%
Net Income Q/Q Growth		 -59.79% 33.14% -11.22% 11.37% 36.94% -48.07% 0.00% -47.91% 20.63% 74.03%
EPS Q/Q Growth		 -44.27% 37.04% -10.08% 11.45% 37.07% 20.55% 0.00% -31.25% 21.43% 72.73%
Operating Cash Flow Q/Q Growth		 -9.22% -4.98% -13.06% 17.25% 33.84% -27.87% 0.00% -42.77% 23.12% 97.84%
Free Cash Flow Firm Q/Q Growth		 -147.95% 7.99% -22.02% 5.95% 22.59% -14.31% 0.00% -28.15% 26.38% 37.20%
Invested Capital Q/Q Growth		 28.30% 67.45% 248.72% 106.76% 82.25% -9.16% 0.00% 16.85% 10.63% 20.29%
Profitability Metrics		 - - - - - - - - - -
Gross Margin		 62.90% 83.62% 71.84% 85.05% 96.90% 83.39% 93.43% 88.77% 87.70% 90.32%
EBITDA Margin		 -14,252.28% -2,266.09% -2,691.69% -1,253.95% -92.70% -440.03% -58.39% -151.94% -78.53% -11.59%
Operating Margin		 -14,448.00% -2,310.84% -2,742.36% -1,286.38% -96.84% -452.23% -63.79% -162.28% -87.29% -10.70%
EBIT Margin		 -14,180.69% -2,198.72% -2,627.04% -1,226.24% -89.70% -432.00% -55.64% -145.34% -77.94% -10.70%
Profit (Net Income) Margin		 -14,856.41% -2,432.25% -2,880.26% -1,367.84% -117.47% -490.05% -71.38% -169.59% -92.81% -15.12%
Tax Burden Percent		 100.00% 100.00% 100.00% 100.00% 107.24% 100.14% 100.92% 100.00% 100.00% 40.50%
Interest Burden Percent		 104.77% 110.62% 109.64% 111.55% 122.11% 113.28% 127.12% 116.69% 119.07% 349.03%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% -756.22% -2,656.30% 0.00% 0.00% 0.00% -54.65%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% -743.95% -2,639.78% 0.00% 0.00% 0.00% -48.98%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 723.35% 2,514.03% 0.00% 0.00% 0.00% 38.27%
Return on Equity (ROE)		 -98.07% -122.80% -166.32% -239.82% -32.87% -142.27% 0.00% 0.00% 0.00% -16.38%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% -4,727.41% -2,312.02% -1,048.10% -1,074.23% -127.32% -87.17% -42.84% -402.47%
Operating Return on Assets (OROA)		 -22.95% -18.90% -45.70% -46.03% -10.97% -65.14% 0.00% 0.00% 0.00% -6.09%
Return on Assets (ROA)		 -24.04% -20.91% -50.10% -51.34% -14.37% -73.89% 0.00% 0.00% 0.00% -8.61%
Return on Common Equity (ROCE)		 -98.07% -122.80% -166.32% -239.82% -32.87% -142.27% 0.00% 0.00% 0.00% -16.38%
Return on Equity Simple (ROE_SIMPLE)		 -114.77% 0.00% -234.19% -410.91% -573.40% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)		 -73 -48 -53 -47 -26 -43 -22 -35 -27 -5.34
NOPAT Margin		 -10,113.60% -1,617.59% -1,919.65% -900.46% -67.79% -316.56% -44.66% -113.60% -61.10% -7.49%
Net Nonoperating Expense Percent (NNEP)		 -10.58% -9.11% -13.14% -17.32% -12.27% -16.52% -7.88% -15.09% -18.45% -5.66%
Return On Investment Capital (ROIC_SIMPLE)		 - -11.76% - - - -14.74% - - - -2.02%
Cost of Revenue to Revenue		 37.10% 16.38% 28.16% 14.95% 3.10% 16.61% 6.57% 11.23% 12.30% 9.68%
SG&A Expenses to Revenue		 4,892.83% 1,250.35% 1,543.26% 885.51% 124.89% 359.86% 110.54% 188.52% 131.42% 80.73%
R&D to Revenue		 9,618.07% 1,144.11% 1,270.95% 485.92% 68.84% 175.77% 46.68% 62.54% 43.57% 20.29%
Operating Expenses to Revenue		 14,548.00% 2,385.38% 2,814.20% 1,371.43% 193.74% 535.63% 157.23% 251.06% 174.99% 101.02%
Earnings before Interest and Taxes (EBIT)		 -103 -65 -73 -64 -34 -58 -28 -45 -35 -7.63
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -103 -67 -75 -65 -35 -60 -29 -47 -35 -8.27
Valuation Ratios		 - - - - - - - - - -
Price to Book Value (P/BV)		 3.64 4.30 4.81 7.27 0.00 3.44 4.16 5.78 6.94 10.35
Price to Tangible Book Value (P/TBV)		 3.74 4.46 5.06 7.94 0.00 3.71 4.28 5.97 7.40 11.01
Price to Revenue (P/Rev)		 1,359.12 244.64 103.90 50.21 0.00 5.11 0.00 0.00 0.00 8.30
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 104.04 48.27 0.00 13.23 31.54 33.75 31.94 41.72
Enterprise Value to Revenue (EV/Rev)		 970.92 186.84 83.09 44.22 0.00 3.92 0.00 0.00 0.00 7.68
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - -
Debt to Equity		 0.73 0.94 1.42 2.48 4.30 2.28 0.90 1.09 1.31 0.68
Long-Term Debt to Equity		 0.73 0.94 1.42 2.48 4.30 2.28 0.90 1.09 0.67 0.68
Financial Leverage		 -1.03 -1.04 -1.03 -1.02 -0.97 -0.95 -0.92 -0.86 -0.76 -0.78
Leverage Ratio		 1.41 1.69 1.89 2.25 2.53 2.65 2.35 2.87 3.59 2.80
Compound Leverage Factor		 1.48 1.87 2.07 2.51 3.08 3.00 2.99 3.35 4.28 9.79
Debt to Total Capital		 42.08% 48.55% 58.72% 71.28% 81.12% 69.47% 47.41% 52.23% 56.64% 40.49%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 27.55% 0.00%
Long-Term Debt to Total Capital		 42.08% 48.55% 58.72% 71.28% 81.12% 69.47% 47.41% 52.23% 29.09% 40.49%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 57.92% 51.45% 41.28% 28.72% 18.88% 30.53% 52.59% 47.77% 43.36% 59.51%
Debt to EBITDA		 -0.66 -0.67 -0.64 -0.64 -0.83 -0.86 0.00 0.00 0.00 -0.81
Net Debt to EBITDA		 0.94 0.72 0.43 0.23 0.11 0.30 0.00 0.00 0.00 0.91
Long-Term Debt to EBITDA		 -0.66 -0.67 -0.64 -0.64 -0.83 -0.86 0.00 0.00 0.00 -0.81
Debt to NOPAT		 -0.92 -0.94 -0.90 -0.90 -1.15 -1.20 0.00 0.00 0.00 -1.19
Net Debt to NOPAT		 1.32 1.01 0.61 0.32 0.16 0.42 0.00 0.00 0.00 1.35
Long-Term Debt to NOPAT		 -0.92 -0.94 -0.90 -0.90 -1.15 -1.20 0.00 0.00 0.00 -1.19
Altman Z-Score		 1.12 0.61 -0.84 -1.94 0.00 -2.70 0.10 -0.17 -0.81 1.98
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - -
Current Ratio		 13.39 11.57 9.93 8.43 6.72 7.08 9.89 8.46 2.46 4.15
Quick Ratio		 12.92 11.06 9.32 7.80 5.89 6.38 9.32 7.90 2.27 3.72
Cash Flow Metrics		 - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -68 -63 -77 -72 -56 -64 -40 -52 -38 -24
Operating Cash Flow to CapEx		 -1,128,250.00% -57,776.42% -97,980.49% -24,088.77% -68,725.00% -937,400.00% 0.00% 0.00% -24,257.34% 0.00%
Free Cash Flow to Firm to Interest Expense		 -13.98 -9.11 -10.92 -9.84 -7.40 -8.24 -5.38 -6.89 -5.71 -4.29
Operating Cash Flow to Interest Expense		 -13.82 -10.28 -11.41 -9.05 -5.82 -7.25 -4.23 -6.03 -5.21 -0.13
Operating Cash Flow Less CapEx to Interest Expense		 -13.82 -10.29 -11.42 -9.08 -5.83 -7.25 -4.23 -6.03 -5.24 -0.13
Efficiency Ratios		 - - - - - - - - - -
Asset Turnover		 0.00 0.01 0.02 0.04 0.12 0.15 0.00 0.00 0.00 0.57
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 4.49 3.48 0.00 0.00 0.00 3.98
Inventory Turnover		 0.00 0.00 0.00 0.00 0.35 0.48 0.00 0.00 0.00 1.38
Fixed Asset Turnover		 0.36 1.78 3.06 5.91 26.70 34.86 0.00 0.00 0.00 152.36
Accounts Payable Turnover		 0.04 0.09 0.12 0.18 0.30 0.48 0.00 0.00 0.00 1.46
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 81.30 104.91 0.00 0.00 0.00 91.81
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 1,030.73 755.62 0.00 0.00 0.00 263.90
Days Payable Outstanding (DPO)		 9,184.02 3,916.25 2,962.63 2,019.34 1,235.81 761.87 0.00 0.00 0.00 250.09
Cash Conversion Cycle (CCC)		 -9,184.02 -3,916.25 -2,962.63 -2,019.34 -123.77 98.65 0.00 0.00 0.00 105.62
Capital & Investment Metrics		 - - - - - - - - - -
Invested Capital		 -11 -3.47 5.17 11 19 18 23 27 30 36
Invested Capital Turnover		 -0.09 -0.33 -0.98 -5.55 11.16 8.39 0.00 0.00 0.00 7.30
Increase / (Decrease) in Invested Capital		 -4.85 15 23 26 30 21 18 17 11 18
Enterprise Value (EV)		 704 689 537 516 0.00 234 734 917 961 1,509
Market Capitalization		 985 902 672 585 0.00 305 935 1,077 1,087 1,630
Book Value per Share		 $5.25 $3.44 $2.29 $1.31 $0.76 $0.94 $2.03 $1.61 $1.34 $1.35
Tangible Book Value per Share		 $5.11 $3.32 $2.17 $1.20 $0.65 $0.87 $1.97 $1.56 $1.26 $1.27
Total Capital		 468 407 338 280 248 290 428 390 361 265
Total Debt		 197 198 199 200 201 202 203 204 205 107
Total Long-Term Debt		 197 198 199 200 201 202 203 204 105 107
Net Debt		 -281 -213 -135 -70 -27 -71 -202 -159 -127 -121
Capital Expenditures (CapEx)		 0.01 0.12 0.08 0.28 0.06 0.01 0.00 0.00 0.14 0.00
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -19 -11 -2.68 2.61 12 11 16 20 20 26
Debt-free Net Working Capital (DFNWC)		 460 400 331 272 240 284 421 383 351 255
Net Working Capital (NWC)		 460 400 331 272 240 284 421 383 251 255
Net Nonoperating Expense (NNE)		 34 24 27 24 19 23 13 17 14 5.45
Net Nonoperating Obligations (NNO)		 -281 -213 -135 -70 -27 -71 -202 -159 -127 -121
Total Depreciation and Amortization (D&A)		 -0.52 -2.00 -1.80 -1.44 -1.15 -1.09 -1.37 -2.04 -0.26 -0.64
Debt-free, Cash-free Net Working Capital to Revenue		 -2,562.76% -304.50% -41.43% 22.42% 23.70% 18.42% 0.00% 0.00% 0.00% 13.35%
Debt-free Net Working Capital to Revenue		 63,395.45% 10,840.99% 5,112.90% 2,335.15% 488.69% 476.06% 0.00% 0.00% 0.00% 129.65%
Net Working Capital to Revenue		 63,395.45% 10,840.99% 5,112.90% 2,335.15% 488.69% 476.06% 0.00% 0.00% 0.00% 129.65%
Earnings Adjustments		 - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($1.89) ($1.19) ($1.31) ($1.16) ($0.73) ($0.58) ($0.32) ($0.42) ($0.33) ($0.09)
Adjusted Weighted Average Basic Shares Outstanding		 57.09M 55.03M 61.17M 61.43M 61.73M 69.31M 111.05M 123.48M 124.30M 120.96M
Adjusted Diluted Earnings per Share		 ($1.89) ($1.19) ($1.31) ($1.16) ($0.73) ($0.58) ($0.32) ($0.42) ($0.33) ($0.09)
Adjusted Weighted Average Diluted Shares Outstanding		 57.09M 55.03M 61.17M 61.43M 61.73M 69.31M 111.05M 123.48M 124.30M 120.96M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 60.93M 61.08M 61.42M 61.65M 94.38M 0.00 115.76M 116.89M 117.04M 118.64M
Normalized Net Operating Profit after Tax (NOPAT)		 -73 -48 -53 -47 -26 -43 -22 -35 -27 -5.34
Normalized NOPAT Margin		 -10,113.60% -1,617.59% -1,919.65% -900.46% -67.79% -316.56% -44.66% -113.60% -61.10% -7.49%
Pre Tax Income Margin		 -14,856.41% -2,432.25% -2,880.26% -1,367.84% -109.53% -489.38% -70.73% -169.59% -92.81% -37.33%
Debt Service Ratios		 - - - - - - - - - -
EBIT to Interest Expense		 -20.99 -9.41 -10.37 -8.66 -4.52 -7.53 -3.69 -5.99 -5.24 -1.37
NOPAT to Interest Expense		 -14.97 -6.93 -7.58 -6.36 -3.42 -5.52 -2.96 -4.68 -4.11 -0.96
EBIT Less CapEx to Interest Expense		 -20.99 -9.43 -10.39 -8.70 -4.53 -7.53 -3.69 -5.99 -5.26 -1.37
NOPAT Less CapEx to Interest Expense		 -14.97 -6.94 -7.59 -6.40 -3.43 -5.52 -2.96 -4.68 -4.13 -0.96
Payout Ratios		 - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Frequently Asked Questions About Arcutis Biotherapeutics' Financials

When does Arcutis Biotherapeutics's financial year end?

According to the most recent income statement we have on file, Arcutis Biotherapeutics' fiscal year ends in December. Their fiscal year 2024 ended on December 31, 2024.

How has Arcutis Biotherapeutics' net income changed over the last 6 years?

Arcutis Biotherapeutics' net income appears to be on an upward trend, with a most recent value of -$140.04 million in 2024, rising from -$19.26 million in 2018. The previous period was -$262.14 million in 2023.

What is Arcutis Biotherapeutics's operating income?
Arcutis Biotherapeutics's total operating income in 2024 was -$128.40 million, based on the following breakdown:
  • Total Gross Profit: $177.41 million
  • Total Operating Expenses: $305.81 million
How has Arcutis Biotherapeutics revenue changed over the last 6 years?

Over the last 6 years, Arcutis Biotherapeutics' total revenue changed from $0.00 in 2018 to $196.54 million in 2024, a change of 19,654,200,000.0%.

How much debt does Arcutis Biotherapeutics have?

Arcutis Biotherapeutics' total liabilities were at $191.35 million at the end of 2024, a 24.3% decrease from 2023, and a 3,347.7% increase since 2019.

How much cash does Arcutis Biotherapeutics have?

In the past 5 years, Arcutis Biotherapeutics' cash and equivalents has ranged from $53.64 million in 2022 to $96.45 million in 2021, and is currently $71.34 million as of their latest financial filing in 2024.

How has Arcutis Biotherapeutics' book value per share changed over the last 6 years?

Over the last 6 years, Arcutis Biotherapeutics' book value per share changed from 0.00 in 2018 to 1.35 in 2024, a change of 134.6%.

Remove Ads

Related Companies

This page (NASDAQ:ARQT) was last updated on 4/15/2025 by MarketBeat.com Staff
From Our Partners
Elon Set to Shock the World by May 1st ?
Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...
Brownstone Research | Sponsored
[Action Required] Claim Your FREE IRS Loophole Guide
This shouldn't surprise anyone who's been paying attention, but... Pres. Trump may be about to unleash the ...
Colonial Metals | Sponsored
Collect $7k per month from Tesla’s SECRET dividend
Tesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...
Investors Alley | Sponsored
Elon’s Silver Play? Trump Clears the Path
Nothing is confirmed—yet. But Musk has disrupted every industry he's touched, and Trump's policies make the ti...
Priority Gold | Sponsored
Get Your Bank Account “Fed Invasion” Ready with THESE 4 Simple Steps
Starting as soon as a few months from now, the United States government will make a sweeping change to bank ac...
Weiss Ratings | Sponsored
Elon Musk Confirms: Tesla’s Optimus is Replacing Workers… and Heading to Mars
Elon Musk just confirmed Tesla’s robot will go to Mars. But on Earth, it may trigger a trillion-dollar tech sh...
InvestorPlace | Sponsored
The Trump Dump is starting; Get out of stocks now?
The first 365 days of the Trump presidency… Will be the best time to get rich in American history.
Paradigm Press | Sponsored
Trump Orders 'National Digital Asset Stockpile'
‘Digital Asset Reserve’ for THIS Coin??? Get all the details before this story gains even more traction
Crypto 101 Media | Sponsored